Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6082 ARTÍCULOS , VIENDO DEL 931 AL 945

Editorial for "Limbic Structural Alterations and Structural Covariance Across Prodromal Phenotypes and Early Parkinson's Disease"

Grist JT.

J Magn Reson Imaging. 2026 Sep 25. doi: 10.1002/jmri.70547. Online ahead of print.

Editorial: Cellular and animal models of neurodegenerative and neuroinflammatory conditions

García-León JA, García-Díaz B, Baglietto-Vargas D, Rodriguez-Ortiz CJ.

Front Cell Neurosci. 2026 Aug 31;20:1961369. doi: 10.3389/fncel.2026.1961369. eCollection 2026.

Blood-Mediated Gut-Brain Axis in Parkinson's Disease: Focus on α-Synuclein Transport and Microbiota Dysbiosis-Induced Inflammation

Xu C, Li W, Ma X, Han L, Cui G, Zhao J, Wang X, Guan Y.

Cells. 2026 Sep 21;15(18):1718. doi: 10.3390/cells15181718.

Moving Beyond the Hyperkinetic Hypothesis for Weight Gain After Deep Brain Stimulation in Parkinson Disease

Eisinger RS, Hamimi SA, Lee JM, Gabriel ED, Halpern CH.

Neuromodulation. 2026 Aug 4:S1094-7159(26)01321-8. doi: 10.1016/j.neurom.2026.07.651. Online ahead of print.

Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making

Jalloul W, Uritu CM, Jalloul D, Ghizdovat V, Vranceanu Ciobanu A, Tamba BI, Stefanescu C, Grierosu IC.

Pharmaceuticals (Basel). 2026 Aug 29;19(9):1369. doi: 10.3390/ph19091369.

Bilirubin and the Yellow Players in Ferroptosis: A Delicate Balance in Human Health and Disease, with a Focus on the Liver, Cardiovascular System, and Brain

Dalla Verde C, Vitek L, Tiribelli C, Gazzin S.

Biomolecules. 2026 Sep 21;16(9):1371. doi: 10.3390/biom16091371.

Multisite study: Predicting Lewy body disease using skin biopsy α-synuclein seed amplification assays

Janarthanam C, Orrú CD, Hughson AG, Holzinger D, Taylor K, Kanthasamy AG, Caughey B, Heym RG, Adler CH, Shill HA, Mehta S, Driver-Dunckley E, Ho AH, Choudhury P, Shprecher DR, Belden CM, Atri A, Zhang N, Chen K, Serrano GE, Beach TG.

J Neuropathol Exp Neurol. 2026 Sep 1;85(9):1020-1032. doi: 10.1093/jnen/nlag048.

Real-world experience with foslevodopa/foscarbidopa in Germany: therapeutic insights and lessons learned

Weise D, Warnecke T, Buhmann C, Ebersbach G, Eggers C, Falkenburger B, Höglinger G, Mollenhauer B, Pedrosa D, Südmeyer M, Weiss D, Kassubek J, Jost WH.

Neurol Res Pract. 2026 Aug 31;8(1):72. doi: 10.1186/s42466-026-00530-3.

Osler Weber Rendu Disease (Hereditary Hemorrhagic Telangiectasia Type 2) Presenting as Acute Reversible Levodopa Responsive Manganese Induced Parkinsonism Following Blood Transfusion: A Case Report

Gurram S, Sangepu N, Gautam G, Varshini A.

Mov Disord Clin Pract. 2026 Sep 4:10.1002/mdc3.70806. doi: 10.1002/mdc3.70806. Online ahead of print.

Intrinsically disordered proteins and liquid-liquid phase separation: Molecular grammar, condensate physiology, and disease-relevant phase transitions

Abinawanto, Sophian A.

Biochim Biophys Acta Proteins Proteom. 2026 Sep 25:141183. doi: 10.1016/j.bbapap.2026.141183. Online ahead of print.

Exercise alone or combined with functional foods in aging and age-related diseases: targeting DNA damage, repair pathways, and genome integrity

Ma Y, Li X, Chen H, Fan R.

Front Aging Neurosci. 2026 Aug 14;18:1772217. doi: 10.3389/fnagi.2026.1772217. eCollection 2026.

Traditional Chinese medicine treatment in a patient with severe COVID-19: A case report

Zhong M, Sun S, Zhang F, Zhang W.

Medicine (Baltimore). 2026 Aug 28;105(35):e50149. doi: 10.1097/MD.0000000000050149.

Co- and multipathologies need serious consideration for understanding Parkinson's disease pathogenesis and designing novel experimental therapeutic strategies

Boehringer A, Kalia LV, Bloem BR, Kordower JH.

J Parkinsons Dis. 2026 Sep 7:1877718X261486172. doi: 10.1177/1877718X261486172. Online ahead of print.

Antibiotics and nanoparticles in Parkinson's disease: From gut microbiota dysbiosis to neuroprotection and targeted nanotherapies

Frangieh MR, Saad M, Fattouh N, Sawan S.

Biomed Pharmacother. 2026 Oct;203:119903. doi: 10.1016/j.biopha.2026.119903. Epub 2026 Sep 4.

Liposomes versus Sphingosomes: Microfluidic DoE-Guided development of lipid nanocarriers for the delivery of a synthetic hMAO inhibitor

Buttitta G, Coluccia M, Bonacorsi S, Diomede F, Marconi GD, Pizzicannella J, Falco E, Guglielmi P.

Int J Pharm. 2026 Sep 5;702:127207. doi: 10.1016/j.ijpharm.2026.127207. Epub 2026 Jul 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias